Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2001

View Archived Issues

VEGF receptor tyrosine kinase inhibitor blocks proliferation, migration of multiple myeloma cells

ASH news: PD-180970 blocks activation of Stat5 and inhibits CML cell growth

Oral HDAC inhibitor MS-275 induces cell cycle arrest, apoptosis and differentiation in AML cells

Clinical efficacy and safety of zosuquidar as a modulator of P-glycoprotein in leukemia and lymphoma

OSI R&D progress highlighted at inaugural research day

Studies at Dana-Farber point to usefulness of beta-lapachone in multiple myeloma

Clinical trials of milnacipran in FMS expected to begin in 2002

Medivir designates candidate drug in HIV/NNRTI research program

Telomerase inhibitor collaboration established by Geron and Ribozyme

Encouraging results reported from phase IIa trial of XTL-001 in chronic hepatitis B patients

GSK and Roche to codevelop and copromote ibandronate

PDL's humanized Zamyl MAb safe and active in refractory/relapsed AML

FDA advisory committee recommends Gliadel Wafer for newly diagnosed malignant glioma

Arixtra receives FDA approval

Phase II trial of Avicine cancer vaccine shows survival benefit

Hexvix cleared for phase III trials in the U.S.

Millennium and Cor Therapeutics announce merger plans

Clofarex designated an orphan drug for leukemia; encouraging clinical findings reported

Novel macrocyclic peptidomimetic antitumor agents in development at U. of Pennsylvania

Trio of pharmaceutical companies jointly design potential agents for bone disorders

Novel compounds for lipid disorders emerge from R&D at Novartis

DuPont researchers identify lactam inhibitors of Abeta production

U.S. academic researchers claim bile acid-containing prodrugs

Preparation and use of CXCR2 receptor modulators disclosed by AstraZeneca

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...